Sentences with phrase «pharmacological activity in»

Many botanicals have pharmacological activity in the body and can be used to treat common health conditions.

Prosecuting would be a «difficult and unworkable task, as little or no evidence is available regarding [the substances»] pharmacological activities in vivo in humans and expert witnesses may be reluctant to extrapolate data from animal models, in silico or in vitro studies,» lecturer in criminal law Amber Marks told the committee.

Not exact matches

Pharmacological inhibition of nutrient uptake decreased CML stem cell activity in vivo.

In their study, the researcher exploited this central position of EZH2 to combat the cancer: They used a pharmacological inhibitor to suppress the activity of EZH2.

It describes itself as «a peer reviewed journal aiming to communicate high quality research articles, short communications, and reviews in the field of natural products with desired pharmacological activities.»

The delay in diagnosis also prevents pharmacological interventions from being initiated, and non-pharmacological activities from being started, such as engaging in diabetes education, discontinuing tobacco use, modifying dietary behaviors and increasing physical activity for improving cardiovascular health and stimulating weight loss.

Paterson, N. E.; Malekiani, S. A.; Foreman, M. M.; Olivier, B.; Hanania, T. Pharmacological characterization of harmaline - induced tremor activity in mice.

Gozzi, A. * Schwarz, A., Reese, T., Bertani, S., Crestan, V., Bifone, A. Region - specific effects of nicotine on brain activity: A pharmacological MRI study in the drug - näve rat (2006) Neuropsychopharmacology, 31 (8), pp. 1690 - 1703

In the research, Rieger treated the zebrafish with pharmacological agents that reduce MMP - 13 activity, with the result that skin defects were improved and chemotherapy - induced nerve damage was reversed.

In vivo pharmacological effects of JZP - 4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activitIn vivo pharmacological effects of JZP - 4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activitin models for anticonvulsant, antimania and antidepressant activity.

These results demonstrate that ABL kinase activity is required for osteolytic metastasis in breast cancer and suggest that pharmacological inhibition of the ABL kinases may be an effective treatment for bone metastasis.

Mice harboring a T106M mutation in p38alpha are resistant to pharmacological inhibition of LPS - induced TNF production and collagen antibody - induced arthritis, indicating that p38beta activity is not required for acute or chronic inflammatory responses.

Di Marzo et al. «Levels, Metabolism, and Pharmacological Activity of Anandamide In CB1, Non-CB2 Receptor - Mediated Actions of Anandamide in Mouse Brain», Journal of Neurochemistry, 75: 2434 - 2444, 200In CB1, Non-CB2 Receptor - Mediated Actions of Anandamide in Mouse Brain», Journal of Neurochemistry, 75: 2434 - 2444, 200in Mouse Brain», Journal of Neurochemistry, 75: 2434 - 2444, 2000.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Intrigued by the plant's traditional use, researchers at Hallym University College of Medicine in Seoul, Institute of Natural Medicine, and Scigenic, a Korean phyto - pharmaceutical company, suspected that one particular constituent of Angelica gigas had powerful pharmacological activity.

The pharmacological activity of each echinacea species appears to reflect the slight variation in the amount of active ingredients and their chemical profiles.

Curcumin (also known by its chemical name, diferuloylmethane) is the major constituent in turmeric and exhibits numerous pharmacological activities that are of interest in oncology.

Melvyn Werbach, M.D., and Michael Murray, N.D., in their book Botanical Influences on Illness (Third Line Press, 1994), say components of licorice exhibit numerous pharmacological actions, including estrogenic activity [24] and aldosteronelike action.